Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01372345 · ClinicalTrials.gov registry record · Phase 1

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions

A Phase 1 study of Fasting, sponsored by Dr. Reddy's Laboratories Limited.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
1
Study location

NCT01372345: Completed Phase 1 study of Fasting, sponsored by Dr. Reddy's Laboratories Limited.

NCT01372345 is a Phase 1 study of Fasting that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 43 participants, below the 204-participant average among 8 other Fasting trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01372345, a Phase 1 study of Fasting, has completed, sponsored by Dr. Reddy's Laboratories Limited.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the relative bioavailability of ciprofloxacin 1000 mg ER tablets of Dr.Reddy's with that of CIPRO® XR 1000 mg of Bayer Pharmaceuticals Corporation in healthy, adult, non-smoking subjects under fasting conditions.

Conditions Studied

Interventions

  • DRUG CIPRO®XR

Study Locations (1)

Texas

  • NOVUM Pharmaceutical Research Services - Houston

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2005-02
Est. Completion 2005-03
Phase Phase 1
Dr. Reddy's Laboratories Limited

52 total trials

What the finished NCT01372345 record still lists

NCT01372345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 204-participant average among 8 other Fasting trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Fasting appearing as the primary indexed condition, and to 1 intervention - of which CIPRO®XR is the first listed.

NCT01372345 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01372345 about?

NCT01372345 is a clinical study titled "Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of ciprofloxacin 1000 mg ER tablets of Dr.Reddy's with that of CIPRO® XR 1000 mg of Bayer Pharmaceuticals Corporation in healthy, adult, non-smoking subjects under fasting conditions.

What is the current status of trial NCT01372345?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2005-02. Estimated completion is 2005-03.

What conditions does trial NCT01372345 study?

This clinical trial studies the following conditions: Fasting.

What interventions are being tested in trial NCT01372345?

The interventions under investigation include: CIPRO®XR (DRUG).

Who is sponsoring clinical trial NCT01372345?

This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01372345 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fasting

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01372345's enrollment target sits among peer trials

43 5th of 8 higher than 4 of 8 other Fasting trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fasting trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01372345, the US trial registry maintained by the National Library of Medicine. NCT01372345 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.